Implanet
ALIMP.PA operates in the healthcare services and equipment industry, primarily engaged in medical equipment, supplies, and distribution.
Business. ALIMP.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALIMP.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
ALIMP.PA exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 14.66, indicating a significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.8, suggesting that it may struggle to meet short-term obligations. Additionally, the company has negative net cash after subtracting total debt, further highlighting its liquidity challenges.
Profitability metrics for ALIMP.PA are severely negative, with a return on equity of -10.85 and a return on assets of -0.24, both well below industry norms. The company reported an operating loss of EUR -4.24 million and a net loss of EUR -4.38 million, indicating a lack of operational efficiency and profitability. These figures suggest that the company is not generating sufficient returns to justify its capital structure or meet investor expectations.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the company's exposure to regional markets is not disclosed. This lack of diversification could expose the company to higher risk if demand in its primary market declines.
ALIMP.PA's growth trajectory is negative, with no indication of revenue growth in the current fiscal year. The company's operating cash flow is negative at EUR -590,000, and free cash flow is also negative at EUR -4.21 million, indicating a lack of cash generation. The company's capital expenditures of EUR -1.17 million suggest ongoing investment, but without corresponding revenue growth, these expenditures may not be justified.
The company faces medium liquidity risk due to its weak current ratio and negative net cash position. While dilution risk is currently low, the company's high debt levels and negative equity could necessitate future equity issuance, which would dilute existing shareholders. The risk assessment highlights the need for close monitoring of the company's liquidity and capital structure.
Recent events, including the latest financial results, show continued losses and negative cash flows. The company's last actual EPS was -0.36 EUR, and its last actual revenue was EUR 6.14 million, indicating a lack of improvement in its financial performance. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational changes.
- ALIMP.PA is highly leveraged with a debt-to-equity ratio of 14.66, indicating a significant reliance on debt financing.
- The company is unprofitable, with a return on equity of -10.85 and a return on assets of -0.24.
- ALIMP.PA has a weak liquidity position, as evidenced by a current ratio of 0.8 and negative net cash after subtracting total debt.
- The company's growth trajectory is negative, with no indication of revenue growth and negative operating and free cash flows.
- The company faces medium liquidity risk and potential dilution risk due to its high debt levels and negative equity.
- "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and potential for margin improvement.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALIMP.PA Market data — financials · 2026-05-27
- Implanet SA Market data — analyst estimates · 2026-05-27